Neogenomics (NEO) Gross Margin (2010 - 2026)

Neogenomics (NEO) has reported Gross Margin for 17 consecutive years, with 43.32% the latest figure, recorded in Q1 2026.

• Gross Margin for Q1 2026 came in at 43.32%, down 27.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 43.15% (down 115.0% YoY), and the FY2025 annual result was 43.21%, down 71.0% from the prior year.
• Gross Margin was 43.32% for Q1 2026 at Neogenomics, down from 43.83% in the prior quarter.
• Over five years, Gross Margin peaked at 44.92% in Q4 2024 and troughed at 32.63% in Q1 2022.
• Average Gross Margin over 5 years is 41.39%, with a median of 42.61% recorded in 2025.
• Year-over-year, Gross Margin tumbled 840 bps in 2022 and surged 732 bps in 2023.
• Over 5 years, Gross Margin stood at 40.97% in 2022, then gained by 6 bps to 43.45% in 2023, then increased by 3 bps to 44.92% in 2024, then retreated by 2 bps to 43.83% in 2025, then fell by 1 bps to 43.32% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 43.32% in Q1 2026, 43.83% in Q4 2025, and 42.84% in Q3 2025.